What made the AUGUSTUS trial such a game-changer and why was it needed?

Professor Lopes describes the 2x2 factorial design which involved 4,600 patients with atrial fibrillation and ACS with or without PCI and independently assessed the contribution on bleeding and on ischaemic events reduction in bleeding with apixaban and warfarin. 

Back to all questions

 

Login/ Register Maximise Minimise